These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 28412732)

  • 1. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
    Watanabe G; Behrns KE; Kim JS; Kim RD
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
    Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
    Shimamura T; Perera SA; Foley KP; Sang J; Rodig SJ; Inoue T; Chen L; Li D; Carretero J; Li YC; Sinha P; Carey CD; Borgman CL; Jimenez JP; Meyerson M; Ying W; Barsoum J; Wong KK; Shapiro GI
    Clin Cancer Res; 2012 Sep; 18(18):4973-85. PubMed ID: 22806877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
    Okamoto J; Mikami I; Tominaga Y; Kuchenbecker KM; Lin YC; Bravo DT; Clement G; Yagui-Beltran A; Ray MR; Koizumi K; He B; Jablons DM
    J Thorac Oncol; 2008 Oct; 3(10):1089-95. PubMed ID: 18827603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.